GGrantIndex
← Search

FLUVOXAMINE TREATMENT OF ASPERGERS SYNDROME

$0M01FY2000RRNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Abstract

Treatment effects of the selective serotonin reuptakae inhibitor, fluvoxamine, in Asperger's syndrome (AS) are being studied. In addition the age-related differences in the pharmacokinetics and pharmacodynamics of fluvoxamine in AS will be examined. Fluvoxamine will be studied in a prospective, open-label study in pre- and post-pubertal subjects ages 6 - 20.

View original record on NIH RePORTER →